Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations

  • Published : 2012.06.30


Objective: To conduct a meta-analysis to investigate the value of EBV DNA in diagnosis of nasopharyngeal cancer (NPC) in Asian populations, and provide important evidence for screening. Methods: Prospective or respective case-control or cohort studies regarding the detection role of EBV DNA for NPC were included in our study. We conducted a comprehensive literature search in PubMed, EMBASE, and the Chinese Biomedical Database (CBM database between January 1980 and March 2012. Results: A total of 18 studies with 1492 NPC cases and 2641 health controls were included. Almost of the included studies were conducted in China, and only one other conducted in Thailand. The overall results demonstrated that the pooled sensitivity, specificity, positive likelihood (+LR) and negative likelihood (-LR) were 0.73 (0.71-0.75), 0.89 (0.88-0.90), 8.84 (5.65-13.84) and 0.19(0.11-0.32), respectively. The overall EBV DNA detection showed the largest area of 0.932 under the summary receiver operator curve (SROC). The accuracy of detection by plasma for NPC (0.86) was higher than in serum (0.81), with largest areas under the SROC of 0.97 and 0.91, respectively. Conclusion: Our results demonstrated the EBV DNA detection in plasma or serum has high sensitivity and specificity in diagnosis of NPC, especially in Chinese populations with a high risk of cancer.


  1. Chan ATC, Lo YMD, Zee B, et al (2002). Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst, 94, 1614-9.
  2. Chang KP, Hsu CL, Chang YL, et al (2008). Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol, 44, 784-92.
  3. Chan KCA, Lo YMD (2002). Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Cancer Biol, 12, 489-96.
  4. Chan KH, Gu YL, Ng F, et al (2003). EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer, 105, 706-9.
  5. Fan H, Nicholls J, Chua D, et al (2004). Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer, 112, 103641.
  6. Feng HY, Huang YJ, Zhou XY, et al (2009). Diagnosis of NPC with Plasma EBV DNA. Journal of Tropical Medicine, 9, 913-5.
  7. Kong P (2010). The clinical value of the quantitative determination of EBV-DNA in blood serum and PBMC patients with nasopharyngeal carcinoma. J Shandong Med College, 32, 321-4.
  8. Leung SF, Tam JS, Chan AT, et al (2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem, 50, 339-45.
  9. Liao LY, Kong M, Liu CJ (2010). Comparison of detection of white blood cell's EBV DNA and plasma's VCA-IgA in nasopharyngeal carcinoma patients. Med Innov China, 7, 145-6.
  10. Lin JC, Chen KY, Wang WY, et al (2001). Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol, 19, 2607-15.
  11. Lo YMD, Chan LY, Chan AT, et al (1999). Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res, 59, 5452-5.
  12. Lo YMD, Chan LYS, Lo KW, et al (1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59, 1188-99.
  13. Lo YMD, Leung S, Chan LY, et al (2000). Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res, 60, 2351-5.
  14. Luo YL, Ou GP, Chi PD, et al (2009). Combined determination of Epstein-barr virus related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chinese Journal of China, 28, 96-9.
  15. Mai S, Zong Y, Zhang M, et al (2002). Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma. Chin Med J, 115, 1895-7.
  16. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al (1998). Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res, 4, 665-9.
  17. Ng WT, Choi CW, Lee MC, et al (2010). Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer, 9, 221-8.
  18. Shao JY, Zhang Y, Li YH, et a1 (2004). Comparison of Epstein- Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma. Anticancer Res, 24, 4059-66.
  19. Sharma TD, Singh TT, Laishram RS, et al (2011).Nasopharyngeal carcinoma--a clinico-pathological study in a regional cancer centre of northeastern India. Asian Pac J Cancer Prev, 12, 1583-7.
  20. Shotelersuk K, Khorprasert C, Sakdikul S, et al (2000). Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res, 6, 1046-51.
  21. Sun JG, Wang HX, Xiao FG, et al (2010). Clinical application of plasma ell free EBV DNA, serum CYFR A21-1 and VCAIgA in patients with nasopharyngeal carcinoma. Modern Oncology, 18, 1930-2.
  22. Sun JG, Zheng AP (2008). Clinical significance of plasma EBV DNA and VCA-IgA for nasopharyngeal carcinoma. Modern Oncol, 16, 2086-7.
  23. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
  24. Tan YJ, Su XK, Cui JH (2010). Comparison of detection of serum VCA-lgA, EA-IgA and EBV-DNA in nasopharyngeal carcinoma patient. Chongqing Med J, 39, 703-6.
  25. Tsang RK, Vlantis AC, Ho RW, et al (2004). Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck, 26, 598-602.
  26. Wei K, Xu Y, Liu J, Zhang W, Liang Z (2010). No incidence trends and no change in pathological proportions of nasopharyngeal carcinoma in Zhongshan in 1970-2007. Asian Pac J Cancer Prev, 11, 1595-9.
  27. Wei WI, Sham JS, Zong YS, et al (1991). The efficacy of fiberoptic endoscopic examination and biopsy in the detection of early nasopharyngeal carcinoma. Cancer, 67, 3127-30.<3127::AID-CNCR2820671231>3.0.CO;2-R
  28. Yang X, Goldstein AM, Chen CJ (2006). Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer, 118, 780-4.
  29. Zeng Y, Zhang LG, Li HY, et al (1982). Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer, 29, 139-41.
  30. Zeng Y, Zhang LG, Wu YC, et al (1985). Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer, 36, 545-7.
  31. Zeng Y, Zhong JM, Li LY, et al (1983). Follow-up studies on Epstein-Barr virus IgA/ VCA antibody-positive persons in Zangwu County, China. Intervirology, 20, 1990-4.
  32. Zhang LW, Luo BQ, Dou XQ, et al (2012). Quantitative analysis of Epstein-Barr virus DNA in saliva, blood serum and peripheral blood cells in patients with nasopharyngeal carcinoma. Chin J Otorhinolaryngol Skull Base Surg, 18, 24-7.
  33. Zhang Y, Gao HY, Feng HX, et al (2004). Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal Carcinoma. Natl Med J Chin, 84, 982-6.
  34. Zhu HF, He X (2012). Significance of detecting plasma EBV DNA and VCA-IgA in patients with nasopharyngeal carcinoma. J Chin Oncol, 18, 111-3.
  35. Zong YS, Sham JS, Ng MH, et al (1992). Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer, 69, 3-7.<3::AID-CNCR2820690104>3.0.CO;2-7

Cited by

  1. Expression of the Pokemon Proto-oncogene in Nasopharyngeal Carcinoma Cell Lines and Tissues vol.14, pp.11, 2013,
  2. Prognostic implication of neuropilin-1 upregulation in human nasopharyngeal carcinoma vol.8, pp.1, 2013,
  3. Microtubule depolymerization activates the Epstein-Barr virus lytic cycle through protein kinase C pathways in nasopharyngeal carcinoma cells vol.94, pp.Pt_12, 2013,
  4. Biomarker discovery of nasopharyngeal carcinoma by proteomics vol.11, pp.2, 2014,
  5. ABO Blood Group, Epstein-Barr virus Infection and Prognosis of Patients with Non-metastatic Nasopharyngeal Carcinoma vol.15, pp.17, 2014,
  6. Diagnostic Significance of Combined Detection of Epstein-Barr Virus Antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for Nasopharyngeal Carcinoma vol.15, pp.5, 2014,
  7. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation vol.32, pp.5, 2014,
  8. Sinonasal Tract Inflammation as a Precursor to Nasopharyngeal Carcinoma vol.154, pp.5, 2016,
  9. The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma vol.155, pp.2, 2016,
  10. Differential prevalence and correlates of whole blood Epstein–Barr virus DNA between HIV-positive and HIV-negative men who have sex with men in Shanghai, China vol.145, pp.11, 2017,
  11. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population vol.18, pp.1, 2018,
  12. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma vol.143, pp.12, 2018,
  13. Assessment of the radiotherapy effect for nasopharyngeal cancer using plasma surface-enhanced Raman spectroscopy technology vol.9, pp.7, 2018,
  14. Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma vol.7, pp.7, 2018,
  15. Apigenin inhibits C5a-induced proliferation of human nasopharyngeal carcinoma cells through down-regulation of C5aR vol.38, pp.3, 2018,
  16. Roles of β-catenin, TCF-4, and survivin in nasopharyngeal carcinoma: correlation with clinicopathological features and prognostic significance vol.19, pp.1, 2019,